Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD

The Pharmacogenomics Journal volume 16, pages 280–285 (2016)Cite this article

Subjects

Abstract

The efficacy of thiopurines, including azathioprine (AZA) and 6-mercaptopurine (6MP), has been demonstrated for the treatment of inflammatory bowel disease (IBD). The most common and serious adverse event of treatment with thiopurines altered by doctors is leukopenia. Hair loss is also a serious event that could be a critical reason for patients to decline thiopurine treatment. Thiopurine-induced severe hair loss causes cosmetic problems, and it takes a long time to recover. In a recent study, NUDT15 R139C was strongly associated with thiopurine-induced leukopenia in Korean and Caucasian populations. In this study, we performed an association study to investigate and replicate the association of R139C with adverse events of thiopurines in Japanese patients. A total of 142 Japanese patients with IBD, with histories of thiopurine treatment, were examined. NUDT15 R139C was genotyped using a custom TaqMan genotyping assay. Adverse events including leukopenia were reviewed from medical records. The 6MP dose was adjusted to AZA equivalents by multiplying with 2 as a thiopurine dose. Five patients developed severe hair loss and all of them were risk homozygous (T/T) for R139C. No early severe hair loss was observed in patients with the C/T or C/C genotype (P=3.82 × 10−16, odds ratio=212). The association of R139C with early (<8 weeks) leukopenia (white blood cells<3000 mm−3), which was previously reported in Korean patients, was replicated in our Japanese IBD cohort (P=1.92 × 10−16, odds ratio=28.4). However, we could not confirm the association with late leukopenia in the Japanese subjects. Patients with the C/T genotype discontinued treatment or required thiopurine dose reduction significantly earlier than patients with the C/C genotype (P=1.45 × 10−4); however, on manipulating the doses, there was no significant difference in the thiopurine continuation rates between the groups. In the maintenance period, the frequencies of 6MP usage were higher, and the doses of thiopurines were significantly lower in patients with the C/T genotype than in those with the C/C genotype (0.574±0.316 mg kg−1 per day vs 1.03±0.425 mg kg−1 per day, P=6.21 × 10−4). NUDT R139C was significantly associated with early severe hair loss in Japanese patients with IBD. We also verified the previously reported association of R139C with early leukopenia in a different East Asian population. It is recommended that treatment with thiopurines should be avoided for patients with the T/T genotype. Low-dose 6MP (0.2–0.3 mg kg−1 per day) could be used rather than AZA for the patients with C/T genotype to continue thiopurine treatments. However, late leukopenia and other several adverse events could not be completely predicted by R139C genotypes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Fraser AG, Orchard TR, Jewell DP . The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485–489.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Willoughby JM, Beckett J, Kumar PJ, Dawson AM . Controlled trial of azathioprine in Crohn's disease. Lancet 1971; 2: 944–947.

    Article  CAS  PubMed  Google Scholar 

  3. Rhodes J, Bainton D, Beck P, Campbell H . Controlled trial of azathioprine in Crohn's disease. Lancet 1971; 2: 1273–1276.

    Article  CAS  PubMed  Google Scholar 

  4. Jewell DP, Truelove SC . Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 1974; 4: 627–630.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383–1395.

    Article  CAS  PubMed  Google Scholar 

  6. Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA . Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2004; 13: 563–567.

    Article  CAS  PubMed  Google Scholar 

  7. Chaparro M, Ordas I, Cabre E, Garcia-Sanchez V, Bastida G, Penalva M et al. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis 2013; 19: 1404–1410.

    Article  PubMed  Google Scholar 

  8. Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB et al. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet 2014; 46: 1131–1134.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Bourgine J, Garat A, Allorge D, Crunelle-Thibaut A, Lo-Guidice JM, Colombel JF et al. Evidence for a functional genetic polymorphism of the Rho-GTPase Rac1. Implication in azathioprine response? Pharmacogenet Genomics 2011; 21: 313–324.

    Article  CAS  PubMed  Google Scholar 

  10. Mazor Y, Koifman E, Elkin H, Chowers Y, Krivoy N, Karban A et al. Risk factors for serious adverse effects of thiopurines in patients with Crohn's disease. Curr Drug Saf 2013; 8: 181–185.

    Article  CAS  PubMed  Google Scholar 

  11. Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025–1030.

    Article  CAS  PubMed  Google Scholar 

  12. Takatsu N, Matsui T, Murakami Y, Ishihara H, Hisabe T, Nagahama T et al. Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol 2009; 24: 1258–1264.

    Article  CAS  PubMed  Google Scholar 

  13. Ban H, Andoh A, Tanaka A, Tsujikawa T, Sasaki M, Saito Y et al. Analysis of thiopurine S-methyltransferase genotypes in Japanese patients with inflammatory bowel disease. Intern Med 2008; 47: 1645–1648.

    Article  PubMed  Google Scholar 

  14. Yang SK, Hong M, Baek J, Choi H, Zhao W, Jung Y et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet 2014; 46: 1017–1020.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Yang SK, Ye BD, Song K . ATG16L1 contributes to Crohn's disease susceptibility in Koreans: overmuch concern for ethnic difference? Gut 2014; 64: 687–688.

    PubMed  Google Scholar 

  16. Yamazaki K, Onouchi Y, Takazoe M, Kubo M, Nakamura Y, Hata A . Association analysis of genetic variants in IL23R, ATG16L1 and 5p13.1 loci with Crohn's disease in Japanese patients. J Hum Genet 2007; 52: 575–583.

    Article  CAS  PubMed  Google Scholar 

  17. Hirano A, Yamazaki K, Umeno J, Ashikawa K, Aoki M, Matsumoto T et al. Association study of 71 European Crohn's disease susceptibility loci in a Japanese population. Inflamm Bowel Dis 2013; 19: 526–533.

    Article  PubMed  Google Scholar 

  18. NCI N, DHHS. National Cancer Institute, Common Terminology Criteria for Adverse Events v4. NIH publication; # 09-7473 2009.

  19. Hibi T, Naganuma M, Kitahora T, Kinjyo F, Shimoyama T . Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol 2003; 38: 740–746.

    Article  CAS  PubMed  Google Scholar 

  20. Takagi Y, Setoyama D, Ito R, Kamiya H, Yamagata Y, Sekiguchi M . Human MTH3 (NUDT18) protein hydrolyzes oxidized forms of guanosine and deoxyguanosine diphosphates: comparison with MTH1 and MTH2. J Biol Chem 2012; 287: 21541–21549.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Tanaka Y, Manabe A, Nakadate H, Kondoh K, Nakamura K, Koh K et al. Methylenetetrahydrofolate reductase gene haplotypes affect toxicity during maintenance therapy for childhood acute lymphoblastic leukemia in Japanese patients. Leuk Lymphoma 2014; 55: 1126–1131.

    Article  CAS  PubMed  Google Scholar 

  22. Stocco G, Yang W, Crews KR, Thierfelder WE, Decorti G, Londero M et al. PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet 2012; 21: 4793–4804.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Roberts RL, Wallace MC, Seinen ML, Krishnaprasad K, Chew A, Lawrance I et al. PACSIN2 does not influence thiopurine-related toxicity in patients with inflammatory bowel disease. Am J Gastroenterol 2014; 109: 925–927.

    Article  CAS  PubMed  Google Scholar 

  24. Bunce M, O'Neill CM, Barnardo MC, Krausa P, Browning MJ, Morris PJ et al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995; 46: 355–367.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank past and present members of the IBD group for fruitful discussions and their scientific contributions.

Author information

Author notes

  1. Y Kakuta and T Naito: These authors contributed equally to this work.

Authors and Affiliations

  1. Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan

    Y Kakuta, T Naito, M Onodera, M Kuroha, T Kimura, H Shiga, K Endo, K Negoro & T Shimosegawa

  2. Health Administration Center, Center for the Advancement of Higher Education, Tohoku University, Sendai, Japan

    Y Kinouchi

Authors
  1. Y Kakuta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Naito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Onodera
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Kuroha
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Kimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H Shiga
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K Endo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K Negoro
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Y Kinouchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. T Shimosegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y Kakuta.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kakuta, Y., Naito, T., Onodera, M. et al. NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD. Pharmacogenomics J 16, 280–285 (2016). https://doi.org/10.1038/tpj.2015.43

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2015.43

This article is cited by

Search

Advanced search

Quick links